Atossa Therapeutics, INC. (ATOS) — SEC Filings

Overview

Atossa Therapeutics, INC. (ATOS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 25, 2026: ATOSSA THERAPEUTICS, INC. (ATOS) is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer, with its lead drug candidate, oral (Z)-endoxifen, currently in Phase 2 clinical development. The company reported a market value of voting and non-voting common equity held

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 5 bearish, 28 neutral, 1 mixed. The dominant filing sentiment for Atossa Therapeutics, INC. is neutral.

Filing Type Overview

Atossa Therapeutics, INC. (ATOS) has filed 3 10-K, 18 8-K, 3 DEF 14A, 5 10-Q, 2 SC 13G/A, 2 SC 13G, 1 8-K/A with the SEC between Mar 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (34)

• Atossa's (Z)-Endoxifen Shows Promise in Breast Cancer Trials — 10-K · Mar 25, 2026 Risk: high
  ATOSSA THERAPEUTICS, INC. (ATOS) is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer, with its lead drug candidate, or
• ATOSSA THERAPEUTICS Files 8-K with Financial Statements — 8-K · Mar 25, 2026
  ATOSSA THERAPEUTICS, INC. filed an 8-K on March 25, 2026, to provide financial statements and exhibits under Item 9.01. This filing includes their 8-K document
• Atossa Seeks Reverse Split to Avoid Nasdaq Delisting — DEF 14A · Dec 22, 2025 Risk: high
  Atossa Therapeutics, Inc. (ATOS) is seeking stockholder approval for a reverse stock split at a ratio between 5:1 and 20:1 to address its non-compliance with Na
• Atossa Therapeutics Files 8-K — 8-K · Dec 4, 2025 Risk: low
  On December 4, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No spe
• Atossa Therapeutics' Q3 Loss Widens Amid Soaring R&D Costs — 10-Q · Nov 12, 2025 Risk: high
  ATOSSA THERAPEUTICS, INC. reported a net loss of $8.692 million for the three months ended September 30, 2025, an increase from a net loss of $7.230 million in
• Atossa Therapeutics Files 8-K on Executive Changes — 8-K · Oct 14, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointm
• Atossa Therapeutics Files 8-K — 8-K · Sep 26, 2025 Risk: low
  On September 26, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or disclosures beyond routine reporting r
• Atossa Therapeutics Files 8-K Report — 8-K · Sep 8, 2025 Risk: low
  On September 8, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indic
• Atossa Therapeutics Faces Delisting Concerns — 8-K · Aug 21, 2025 Risk: high
  Atossa Therapeutics, Inc. filed an 8-K on August 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The compa
• Atossa Therapeutics Files 8-K for Financial Reporting — 8-K · Aug 12, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as financial statements and e
• Atossa Therapeutics Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including assets and liabilities, and p
• Atossa Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 12, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed an 8-K on May 12, 2025, reporting on a submission of matters to a vote of security holders. The earliest event reported was on M
• Atossa Therapeutics Files 8-K Report — 8-K · Apr 7, 2025 Risk: low
  On April 7, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure, with no specific financi
• Atossa Therapeutics Executive Compensation Details — DEF 14A · Mar 26, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed a DEF 14A on March 26, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
• Atossa Therapeutics Files 2024 10-K — 10-K · Mar 25, 2025 Risk: medium
  Atossa Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 25, 2025. The report details the company's financial performance
• Atossa Therapeutics Files 8-K Report — 8-K · Mar 12, 2025 Risk: low
  On March 11, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
• Atossa Therapeutics Faces Delisting Concerns — 8-K · Feb 24, 2025 Risk: high
  Atossa Therapeutics, Inc. filed an 8-K on February 24, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of Fe
• Atossa Therapeutics Files 8-K — 8-K · Feb 4, 2025 Risk: low
  On January 30, 2025, Atossa Therapeutics, Inc. filed an 8-K report to disclose other events and financial statements. The filing does not contain specific detai
• Atossa Therapeutics Files 8-K with Financials — 8-K · Dec 10, 2024 Risk: low
  On December 10, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corpora
• Atossa Therapeutics Enters Material Definitive Agreement — 8-K · Nov 19, 2024 Risk: medium
  On November 19, 2024, Atossa Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement,
• Atossa Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Atossa Therapeutics, Inc. filed its Q3 2024 10-Q report on November 12, 2024, detailing its financial performance for the period ending September 30, 2024. The
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Atossa Therapeutics Files 8-K — 8-K · Nov 4, 2024 Risk: low
  On November 4, 2024, Atossa Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• Atossa Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
  Atossa Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including common stock, additional
• Atossa Therapeutics Files 8-K: Director Changes & Officer Compensation Updates — 8-K · Jul 2, 2024 Risk: medium
  On June 27, 2024, Atossa Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new dir
• Atossa Therapeutics Files Definitive Proxy Statement — DEF 14A · May 23, 2024 Risk: medium
  Atossa Therapeutics, Inc. filed its definitive proxy statement on May 23, 2024, for its annual meeting of stockholders. The filing outlines the proposals to be
• Atossa Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  ATOSSA THERAPEUTICS, INC. (ATOS) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Atossa Therapeutics, Inc. filed a 10-Q report for the period endi
• Atossa Therapeutics Files 8-K/A Amendment — 8-K/A · Apr 2, 2024 Risk: low
  Atossa Therapeutics, Inc. filed an 8-K/A on April 1, 2024, to amend its previous filing regarding financial condition and results of operations. The amendment p
• Atossa Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  ATOSSA THERAPEUTICS, INC. (ATOS) filed a Annual Report (10-K) with the SEC on April 1, 2024. Atossa Therapeutics, Inc. filed its annual report on Form 10-K for
• Atossa Therapeutics Faces Delisting, Plans Reverse Stock Split — 8-K · Mar 18, 2024 Risk: high
  Atossa Therapeutics, Inc. filed an 8-K on March 18, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is address
• Atossa Therapeutics Files 8-K with Board and Compensation Updates — 8-K · Mar 12, 2024 Risk: medium
  Atossa Therapeutics, Inc. filed an 8-K on March 12, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also i

Risk Profile

Risk Assessment: Of ATOS's 29 recent filings, 6 were flagged as high-risk, 14 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Atossa Therapeutics, INC.'s most recent 10-K filing (Mar 25, 2026):

• Revenue: Not Disclosed
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Steven C. Quay, M.D., Ph.D.
• Steven C. Quay

Industry Context

The biopharmaceutical industry, particularly the oncology sector, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Atossa Therapeutics operate in a competitive landscape with established players and numerous emerging biotechs vying for market share. Key trends include the development of targeted therapies, personalized medicine, and novel approaches to address unmet medical needs in cancer treatment and prevention.

Top Tags

8-k (6) · sec-filing (5) · financials (5) · 8-K (4) · 10-Q (4) · delisting (3) · regulatory-filing (3) · financial-reporting (3) · corporate-governance (3) · Oncology (2)

Key Numbers

• Aggregate market value of common equity held by non-affiliates: $107,145,637 — as of June 30, 2025, indicating company size and liquidity
• Shares of common stock outstanding: 8,611,361 — as of March 17, 2026
• Patent protection expiry for (Z)-endoxifen: November 17, 2038 — provides long-term intellectual property protection
• Mean MBD reduction with 1 mg (Z)-endoxifen: 17.3% — significant reduction compared to placebo in Karisma study
• Mean MBD reduction with 2 mg (Z)-endoxifen: 23.5% — significant reduction compared to placebo in Karisma study
• Change in MBD in placebo group: 0.27% — demonstrates efficacy of (Z)-endoxifen over placebo
• Median MRI functional tumor volume reduction: 72% — observed in I-SPY 2 study with 10 mg (Z)-endoxifen
• Average Ki-67% at baseline in I-SPY 2: 16% — decreased to 10% at week 3, indicating anti-proliferative activity
• Average Ki-67% at week 3 and surgery in I-SPY 2: 10% — demonstrates sustained anti-proliferative effect
• Nasdaq minimum bid price: $1.00 — ATOS failed to maintain this price for 30 consecutive business days
• ATOS closing price: $0.73 — Closing price on December 19, 2025, below Nasdaq minimum
• Reverse stock split ratio range: 5:1 to 20:1 — Proposed range for the reverse stock split
• Nasdaq compliance deadline: February 17, 2026 — Final deadline for ATOS to regain Nasdaq listing compliance
• Shares outstanding: 129,171,424 — Total common shares issued and outstanding on the Record Date
• Proxy solicitation cost: $16,000 — Estimated cost for retaining Alliance Advisors

Frequently Asked Questions